Larimar Therapeutics (LRMR) Cash from Operations (2013 - 2025)
Larimar Therapeutics (LRMR) posted Cash from Operations of 19381000.0 for Q2 2025, up 26.97% on a QoQ basis from 26540000.0 in Q1 2025, and down 38.55% year-over-year from 31541760.09 in Q2 2024.
Larimar Therapeutics (LRMR) Cash from Operations (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Cash from Operations history runs 13 years deep, the most recent figure standing at 19381000.0 for Q2 2025.
- Quarterly Cash from Operations fell 38.55% year-over-year to 19381000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 92282000.0 (down 114.69% YoY) and the FY2025 annual result came in at 113200000.0, down 59.98% from the prior year.
- Cash from Operations was 19381000.0 for Q2 2025 at Larimar Therapeutics, up from 26540000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5878000.0 in Q3 2022 and bottomed at 26540000.0 in Q1 2025.
- A 5-year average of 12214166.67 and a median of 9897500.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 51.82% — and 2024, when it sank 166.8%.
- Larimar Therapeutics' Cash from Operations stood at 7918000.0 in 2021, then advanced by 15.74% to 6672000.0 in 2022, then slumped by 40.65% to 9384000.0 in 2023, then slumped by 132.47% to 21815000.0 in 2024, then rose by 11.16% to 19381000.0 in 2025.
- Business Quant data shows LRMR's Cash from Operations at 19381000.0 in Q2 2025, 26540000.0 in Q1 2025, and 21815000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -19.38 Mn |
| Jun 30, 2025 | -19.38 Mn |
| Mar 31, 2025 | -26.54 Mn |
| Mar 31, 2025 | -26.54 Mn |
| Dec 31, 2024 | -21.82 Mn |
| Dec 31, 2024 | -21.82 Mn |
| Sep 30, 2024 | -24.55 Mn |
| Sep 30, 2024 | -24.55 Mn |
| Jun 30, 2024 | -13.99 Mn |
| Jun 30, 2024 | -13.99 Mn |
| Mar 31, 2024 | -10.41 Mn |
| Mar 31, 2024 | -10.41 Mn |
| Dec 31, 2023 | -9.38 Mn |
| Dec 31, 2023 | -9.38 Mn |
| Sep 30, 2023 | -9.20 Mn |
| Sep 30, 2023 | -9.20 Mn |
| Jun 30, 2023 | -7.37 Mn |
| Jun 30, 2023 | -7.37 Mn |
| Mar 31, 2023 | -7.55 Mn |
| Mar 31, 2023 | -7.55 Mn |